EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

HO-1197 as a Multifaceted Therapeutic: Targeting the Cell Cycle, Angiogenesis, Metastasis, and Tumor Immunity in Hepatocellular Carcinoma

Yeonhwa Song, Seungeun Lee, So-Won Heo, Juliane Spohn, Dominik Schmiedel iD, Taemoo Heo, Sanghwa Kim, Jongmin Park, Haeng Ran Seo

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms262110329 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Yeonhwa Song und 8 weiteren Autor:innen. Beteiligte Einrichtung: Advanced Biomedical Research Lab, Institut Pasteur Korea, 16, Daewangpangyo-ro 712 beon-gil, Bundang-gu, Seongnam-si 13488, Gyeonggi-do, Republic of …. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Neovascularization, Pathologic, Cell Cycle. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: H&O Biosis, Korea government, H&O Biosis Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) is the most prevalent primary malignancy of the liver. Characterized by rapid progression and poor overall survival rates, HCC requires effective and streamlined treatment regimens. It predominantly occurs in East Asia and sub-Saharan Africa, where it has historically been managed with herbal formulas. We previously observed that the herbal formula HO-1089 exerts potent anti-HCC effects both in vitro and in vivo. In this study, we investigated the anticancer efficacy and mechanisms of HO-1197, a reconstituted herbal formulation derived from HO-1089. HO-1197 selectively inhibited the viability of HCC cell lines without hepatotoxicity and demonstrated superior anticancer activity compared with both HO-1089 and sorafenib. Mechanistically, HO-1197 induced apoptosis and G2/M arrest through reactive oxygen species-mediated DNA damage, independent of p53 status. Transcriptomic analysis revealed downregulation of mitosis-related genes, particularly those regulated by FOXM1, a key driver of HCC proliferation and metastasis. HO-1197 suppressed FOXM1 expression and nuclear translocation, reducing its downstream targets and diminishing angiogenic and metastatic potential. Furthermore, HO-1197 modulated the tumor immune microenvironment by promoting pro-inflammatory macrophage polarization and enhancing natural killer cell-mediated cytotoxicity. HO-1197 exhibited potent antitumor efficacy, and combination therapy with HO-1197 and sorafenib exhibited synergistic effects in both two-dimensional and immune-activated multicellular spheroid models. These findings suggest that HO-1197 is a promising multifunctional therapeutic candidate with antitumor, antiangiogenic, antimetastatic, and immunomodulatory properties. Its combination with sorafenib may offer effective treatment for HCC. HO-1197, which demonstrated strong efficacy, is a novel herbal medicine developed by H&O Biosis and is referred to as an Integrated Natural Medicine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsNeovascularization, PathologicCell CycleHumansAnimalsCell Line, TumorMiceApoptosisForkhead Box Protein M1Neoplasm MetastasisTumor MicroenvironmentSorafenibCell ProliferationGene Expression Regulation, NeoplasticAngiogenesis

Stichwörter der Autor:innen

FOXM1angiogenesiscell cycle arresthepatocellular carcinoma (HCC)immune modulationmetastasis

Substanzen

Forkhead Box Protein M1Sorafenib

Autor:innen und Institutionen

  • Advanced Biomedical Research Lab, Institut Pasteur Korea, 16, Daewangpangyo-ro 712 beon-gil, Bundang-gu, Seongnam-si 13488, Gyeonggi-do, Republic of Korea.
  • Department of Advanced Drug Discovery & Development, Institut Pasteur Korea (IPK) School, University of Science and Technology (UST), 16, Daewangpangyo-ro 712 Beon-gil, Bundang-gu, Seongnam-si 13488, Gyeonggi-do, Republ…
  • Department for Bio- and Nanotechnology, Fraunhofer Institute for Ceramic Technologies and Systems (IKTS), Perlickstr. 1, 04103 Leipzig, Germany.
  • Department for Cell and Gene Therapy Development, Fraunhofer Institute for Cell Therapy and Immunology (IZI), Perlickstr. 1, 04103 Leipzig, Germany.
  • H&O Biosis Co., Ltd., 19-10, Jeongnamsandan-ro, Jeongnam-myeon, Hwaseong-si 18514, Gyeonggi-do, Republic of Korea.

ORCID-Profile: Dominik Schmiedel

Förderung

  • H&O Biosis
  • Korea government
  • H&O Biosis Co., Ltd.

Zitieren

APA

Song, Y., Lee, S., Heo, S. W., Spohn, J., Schmiedel, D., Heo, T., Kim, S., Park, J., & Seo, H. R. (2025). HO-1197 as a Multifaceted Therapeutic: Targeting the Cell Cycle, Angiogenesis, Metastasis, and Tumor Immunity in Hepatocellular Carcinoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262110329

Vancouver

Song Y, Lee S, Heo SW, Spohn J, Schmiedel D, Heo T, et al. HO-1197 as a Multifaceted Therapeutic: Targeting the Cell Cycle, Angiogenesis, Metastasis, and Tumor Immunity in Hepatocellular Carcinoma. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262110329

BibTeX
@article{Song2025,
  author = {Song, Yeonhwa and Lee, Seungeun and Heo, So-Won and Spohn, Juliane and Schmiedel, Dominik and Heo, Taemoo and Kim, Sanghwa and Park, Jongmin and Seo, Haeng Ran},
  title = {HO-1197 as a Multifaceted Therapeutic: Targeting the Cell Cycle, Angiogenesis, Metastasis, and Tumor Immunity in Hepatocellular Carcinoma},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms262110329}
}
Kostenlos starten →